Cyclus (YCDGFYACYMDV)

Cyclic (YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis) . The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model[1].

535959-77-4

12352209

Apoptosis; EGFR

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-programmed cell death

Cancer

O=C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)NC2=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@H]2C)=O)=O)=O)=O)=O)[C@H](CC5=CC=C(C=C5)O)N

C65H82N12O20S3

1447.61

[1]Zhang L, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Feb;15 (2) :145-153.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10793/

Peptides

No Development Reported

ErbB2/HER2